ERYP.PA - ERYTECH Pharma S.A.

Paris - Paris Delayed Price. Currency in EUR
8.38
-0.06 (-0.71%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close8.44
Open8.69
Bid0.00 x 0
Ask0.00 x 0
Day's Range8.17 - 8.69
52 Week Range8.17 - 29.70
Volume66,916
Avg. Volume57,116
Market Cap150.316M
Beta1.96
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateNov 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.04
  • Benzinga4 days ago

    The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...

  • GlobeNewswire5 days ago

    ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer

    LYON, France and CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named `TRYbeCA1`, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer. The TRYbeCa1 (NCT03665441) trial will enroll approximately 500 patients with second line metastatic pancreatic cancer in 120-130 clinical sites in Europe and the US. Patients who meet the eligibility criteria are randomized 1-to-1 to receive eryaspase in combination with standard chemotherapy (gemcitabine/abraxane  or irinotecan -based regimen) or chemotherapy alone until disease progression.

  • GlobeNewswire5 days ago

    ERYTECH Announces Enrollment of First Patients in Phase 3 Clinical Trial Evaluating Eryaspase for the Treatment of Second Line Pancreatic Cancer

    ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first three patients have been enrolled in its pivotal Phase 3 clinical trial, named ‘TRYbeCA1’, evaluating its lead product candidate eryaspase for the treatment of second line metastatic pancreatic cancer. The TRYbeCa1 (NCT03665441) trial will enroll approximately 500 patients with second line metastatic pancreatic cancer in 120-130 clinical sites in Europe and the US. Patients who meet the eligibility criteria are randomized 1-to-1 to receive eryaspase in combination with standard chemotherapy (gemcitabine/abraxane  or irinotecan -based regimen) or chemotherapy alone until disease progression.

  • GlobeNewswire11 days ago

    ERYTECH to Attend Upcoming Investor Conferences

    LYON, France, Sept. 13, 2018 (GLOBE NEWSWIRE) --  ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug ...

  • GlobeNewswire12 days ago

    ERYTECH to Attend Upcoming Investor Conferences

    LYON, France, Sept. 13, 2018-- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that members ...

  • Who Owns Most Of ERYTECH Pharma SA (EPA:ERYP)?
    Simply Wall St.14 days ago

    Who Owns Most Of ERYTECH Pharma SA (EPA:ERYP)?

    If you want to know who really controls ERYTECH Pharma SA (EPA:ERYP), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company grows,Read More...

  • GlobeNewswire14 days ago

    ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update

    Conference call and webcast scheduled for Tuesday, September 11 th at 2:30 pm CET/8:30 am EDT Strategic shift to development of eryaspase for solid tumors confirmed Phase 3 trial for eryaspase in second ...

  • GlobeNewswire14 days ago

    ERYTECH Reports First Half of 2018 Financial Results and Provides Business Update

    ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today provided a business update and reported its financial results for the quarter ended June 30, 2018. “In the first half of 2018, we completed our strategic transition towards solid tumor indications of high unmet medical need,” said Gil Beyen, Chief Executive Officer at ERYTECH.

  • GlobeNewswire19 days ago

    ERYTECH to Host Second Quarter 2018 Conference Call and Business Update

    LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) --  ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...

  • GlobeNewswire19 days ago

    ERYTECH to Host Second Quarter 2018 Conference Call and Business Update

    LYON, France, Sept. 06, 2018-- ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced ...

  • GlobeNewswire19 days ago

    Erytech Pharma S.A. : Monthly information related to total number of voting rights and shares composing the share capital - August 31, 2018

    Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France Listing markets:  Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) &  ...

  • GlobeNewswire2 months ago

    ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018

    LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. ...

  • GlobeNewswire2 months ago

    ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018

    LYON, France and CAMBRIDGE, Mass., July 17, 2018-- ERYTECH Pharma announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018.. At the meeting, all resolutions for which ...

  • GlobeNewswire2 months ago

    Monthly information related to total number of voting rights and shares composing the share capital - June 30, 2018

    Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon - France   ERN France, July 12, 2018 (GLOBE NEWSWIRE) --  Monthly information related to total number of voting rights ...

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 25) Quest Diagnostics Inc (NYSE: DGX )(Barclays upgraded shares ...

  • GlobeNewswire3 months ago

    ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

    Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. LYON, France and CAMBRIDGE Mass., June 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP.PA) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.

  • GlobeNewswire3 months ago

    ERYTECH to Present at JMP Securities Life Science Conference

    LYON, France, June 20, 2018 (GLOBE NEWSWIRE) --  ERYTECH Pharma  (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic ...

  • GlobeNewswire3 months ago

    ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

    LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP.PA) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden. The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH`s R&D Project Leader.

  • GlobeNewswire4 months ago

    Erytech Pharma S.A. : General Meeting to be held on June 28, 2018 and Availability of Related Materials

    LYON, France, June  07, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer ...

  • GlobeNewswire4 months ago

    Monthly information related to total number of voting rights and shares composing the share capital -May 31, 2018

    Article 223-16 of general regulation of French Autorité des Marchés Financiers ERN France, June 06, 2018 (GLOBE NEWSWIRE) --  Monthly information related to total number of voting rights and shares composing ...

  • GlobeNewswire4 months ago

    ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018

    LYON, France, June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYP.PA) (ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present pharmacodynamic characterization data from its Phase 2/3 trial of eryaspase (GRASPA®) in combination with chemotherapy for the treatment of relapsed acute lymphoblastic leukemia (ALL) at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, Illinois. Poster Session: Pharmacodynamic Characterization of eryaspase (L-asparaginase Encapsulated in Red Blood Cells) in Combination with Chemotherapy in a Phase 2/3 Trial in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517).